NCT02548078View on ClinicalTrials.gov

A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children

PHASE2CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

November 9, 2015

Primary Completion Date

May 15, 2017

Study Completion Date

May 15, 2017

Conditions
Virus Diseases
Interventions
BIOLOGICAL

GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)

A single dose administered intramuscular

BIOLOGICAL

Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine

A single dose administered intramuscular

Trial Locations (2)

Unknown

GSK Investigational Site, Bamako

GSK Investigational Site, Dakar

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02548078 - A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children | Biotech Hunter | Biotech Hunter